Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(TSX:BLCO)

23.63 +0.38 (+1.63%)
Streaming Delayed Price Updated: 10:30 AM EDT, Jul 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 406
Open 23.57
Bid (Size) 23.56 (1)
Ask (Size) 23.65 (1)
Prev. Close 23.25
Today's Range 23.57 - 23.70
52wk Range 18.24 - 25.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
From Bausch + Lomb
Via Business Wire
News headline image
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29
From Bausch + Lomb Corporation
Via Business Wire

Performance

YTD
+3.7%
+3.7%
1 Month
+12.0%
+12.0%
3 Month
+5.0%
+5.0%
6 Month
-2.0%
-2.0%
1 Year
+23.2%
+23.2%

More News

Read More
News headline image
New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Launches PreserVision AREDS3™ Eye Vitamins in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Second R&D “Teach-in” Webinar
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Releases 2025 Sustainability Impact Report
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Launches R&D “Teach-in” Webinar Series
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Completes Refinancing of Outstanding Term B Loans
From Bausch + Lomb Corporation
Via Business Wire

Frequently Asked Questions

Is BLCO publicly traded?
Yes, BLCO is publicly traded.
What exchange does BLCO trade on?
BLCO trades on the Toronto Stock Exchange
What is the ticker symbol for BLCO?
The ticker symbol for BLCO is BLCO on the Toronto Stock Exchange
What is the current price of BLCO?
The current price of BLCO is 23.63
When was BLCO last traded?
The last trade of BLCO was at 07/09/26 10:30 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.